AXSM Axsome Therapeutics Inc
Company Analysis
Latest News
Axsome Therapeutics Attracts OMERS Stake, Driven by Surging Auvelity Sales
OMERS Administration Corp purchased 50,671 shares of Axsome Therapeutics, Inc. The new position is valued at approximately $12.4 million according to a recent...
🔴 Axsome Therapeutics is trading 4.2% down today amid biotech profit-taking
Axsome Therapeutics is trading 4.2% down at $209.04, mainly amid biotechnology profit-taking and broader risk-off trading. - No fresh company-specific...
Axsome Posts 46% Revenue Growth and a New Drug Filing — But Can It Turn Momentum Into Profit Before Cash Runs Thin?
Shares of Axsome Therapeutics surged 6% to $234.24 after the brain-health drugmaker reported Q2 results that showed accelerating demand across its product...
🟢 Axsome Therapeutics is trading 6% up in pre-market after 46% Q2 revenue growth
Axsome Therapeutics is trading 6.04% up at $234.24 after August 10, 2026, Q2 results highlighted 46% revenue growth and accelerating AUVELITY demand. -...
🟢 Axsome Therapeutics is trading 4.35% up today after reporting 46% year-over-year revenue growth
Axsome Therapeutics is trading 4.35% up at $222 after reporting second-quarter revenue of $218.4 million, up 46% year over year, driven by Auvelity sales and...
Axsome Therapeutics' second quarter 2026 revenue grew 46% as Auvelity sales beat estimates
Axsome Therapeutics reported second quarter 2026 total revenue of $218.4 million, a 46% year-over-year increase, primarily driven by the performance of its...
Axsome Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 10, 2026
Axsome Therapeutics is expected to report Q2 2026 revenue of $221.11 million and a consensus loss of $0.99 per share, with the stock currently trading at...
🔴 Axsome Therapeutics is trading 4.1% down today after BlackRock reduces stake by 30%
Axsome Therapeutics is trading 4.1% down today at $208.96 following news that BlackRock significantly reduced its position in the company. • BlackRock...
BlackRock Substantially Reduces Stake in Axsome Therapeutics by 30%
On August 1, 2026, it was reported that BlackRock Inc. had significantly reduced its stake in Axsome Therapeutics, selling 1,176,341 shares on June 30, 2026....
🔴 Axsome Therapeutics is trading 5.2% down today on profit-taking after a multi-week rally
Axsome Therapeutics is trading 5.2% down at $222.35 as investors lock in gains following a strong multi-week rally fueled by enthusiasm for its CNS drug...
🔴 Axsome Therapeutics is trading 5.2% down today on potential profit-taking after last week's gains
Axsome Therapeutics is trading at $225.99 (5.2% down) in pre-market as the stock pulls back from last week's rally in the absence of new catalysts. • No fresh...
🔴 Axsome Therapeutics is trading 4.2% down today with no clear company-specific catalyst found
Axsome Therapeutics is trading at $231.00 (-4.15%) in after-hours trading following a session with no confirmed company-specific news to account for the...
Axsome Therapeutics Eyes $310 Target, Following BMO Capital Outperform Rating
BMO Capital initiated coverage of Axsome Therapeutics Inc. on July 21, 2026. The firm issued an Outperform rating for the stock. Analysts set a price target of...
🟢 Axsome Therapeutics is trading 4.1% up today amid biotech sector gains and CNS pipeline optimism
Axsome Therapeutics is trading 4.1% up now at $230.64, rebounding after recent pullbacks amid strong biotech sector gains and optimism surrounding its CNS...
Axsome Announces FDA Acceptance of New Drug Application for AXS-12 in Narcolepsy
Axsome Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for AXS-12 (reboxetine),...
🔴 Axsome Therapeutics is trading 4.3% down today on profit-taking after recent FDA label expansion rally
Axsome Therapeutics is trading at $238.24 (4.3% down) as investors lock in gains following a significant rally driven by regulatory milestones and strong...
🟢 AXSM surges 4.1% today on Phase 3 trial initiation for ADHD treatment
AXSM is trading 4.1% up now at $252.41 following the initiation of its FOCUS-2 Phase 3 trial for solriamfetol in children with ADHD. • This significant...
🔴 AXSM is trading 4% down today as investors take profits after a post-earnings rally
AXSM is trading at $234.97 (4% down) in pre-market, pulling back from a strong run following its Q1 2026 earnings and Auvelity-related optimism. • The stock...
🟢 AXSM is trading 4.1% up today after TD Cowen raised its price target following Auvelity's FDA approval
AXSM is trading 4.1% up at $247.06 as the stock extends a strong multi-week rally driven by positive regulatory developments and bullish analyst sentiment. •...
🔴 Axsome Therapeutics Inc is trading 35.3% down today with no clear company-specific catalyst
Axsome Therapeutics Inc is trading at $163.19 (-35.28%) in after-hours trading following a sharp drop from the regular-session close, despite no immediate...